Acquisition leverage FlexBiosys was acquired by Repligen in September 2023, indicating access to expanded resources, broader product offerings, and potential cross-selling opportunities for bioprocess containers, manifolds, and related accessories.

SMB with niche Employee size sits in the 11-50 range, suggesting a small to mid-size operation with agility and opportunities for high-touch sales, custom solutions, and shorter lead times in bioprocessing consumables.

US-based manufacturing Manufactures in New Jersey within an ISO Class 7 cleanroom, presenting compliance and quality advantages for U.S.-focused biopharma customers seeking reliable domestic supply chains and onshore continuity.

Certifications as proof SBA 8a, WBENC-Certified WBE and WOSB, and ISO 9001:2015 credentials can be leveraged to target government, minority-owned, and diverse supplier programs, expanding potential procurement opportunities.

Growth signals Recent coverage notes Repligen’s interest in fluid management offerings and the company’s presence on Forbes fastest-growing list, signaling a growth trajectory and potential for scale-up collaborations.